source
- Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s PatientsCognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
- Merck halts development of BTK inhibitor nemtabrutinib after safety concernsMerck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…